A closed-loop control system was constructed for automatic intravenous infusion of insulin to control blood sugar levels (BSL) in critically ill patients. We describe the development of the system. A total of nine subjects were recruited to clinically test the control system. In the patients who underwent closed-loop control of BSL, the controller managed to control only one patient's glycaemia without any manual intervention. The average BSL attained during closedloop control approached the target range of 6-10 mmol/l, and had less deviation than when BSL had been maintained manually.
Closed-loop control of blood sugar levels (BSL) has been a research topic since the 1970s. The aim of the system is to mimic the effect of the normal endocrine pancreas. Diabetic patients are required to measure BSL manually and determine an appropriate insulin dose. In sedated patients in the intensive care unit (ICU), medical staff manually control BSL on behalf of the patient. Insulin is usually given by intravenous bolus or infusion in response to elevated BSL readings for patients in the ICU.
In a closed-loop feedback system, a blood glucose sensor measures blood glucose level (or a surrogate of this level) continuously. A controller, using an algorithm, then regulates the insulin delivery to the patient via an infusion pump 1, 2 .
Previous experience has shown that closed-loop BSL control using real-time continuous measure-ments of venous whole blood glucose level is viable and effective in glycaemic regulation [3] [4] [5] . Older systems however suffered many problems with the glucose sensor, limiting the length of treatment possible [6] [7] [8] . The portability of the older systems was also very limited 1, 7 .
Recent research attention has been directed to the use of minimally invasive and non-invasive methods to measure BSL 9, 10 . Minimally invasive techniques (e.g. glucose sensor in the subcutaneous space) have been reported to achieve good on-line agreement with whole blood BSL [11] [12] [13] . Good glycemic control has been demonstrated with a closed-loop control system using a subcutaneously implanted glucose sensor [14] [15] [16] . The preparation required for use of subcutaneous sensors has been laborious until the advent of new sensor manufacturing techniques. These techniques have resulted in an electroenzymatic sensor 17, 18 . An example is the MiniMed ® (Slymar, CA) Continuous Glucose Monitoring System (CGMS).
The CGMS allows subcutaneous glucose measurement with minimal preparation. It also allows the concept of closed-loop feedback control to be re-visited 19 .
This study investigates the viability of closed-loop feedback control using the MiniMed ® CGMS in realtime. At the time of reporting, CGMS is the only commercially available, minimally invasive blood glucose sensor approved by the FDA (Food and Drug Administration, U.S.A.). This paper describes the development and clinical testing of a closed-loop BSL control system in patients rendered hyperglycaemic by critical illness.
MATERIALS AND METHODS

System Description
The closed-loop insulin delivery system is comprised of three components as shown in Figure 1 .
The Sensor
The minimally invasive blood glucose sensor used in our system is the MiniMed ® Continuous Glucose Monitoring System (CGMS). It consists of a disposable subcutaneous glucose sensor connected to a pager-sized glucose monitor by a cable (Figure 2 ). The enzyme glucose-oxidase is covalently bonded onto the sensor surface, and is used to convert glucose at the sensor surface into electronic signals 20 . CGMS takes a glucose measurement every 10 seconds, and stores and reports a smoothed average of these values every five minutes.
CGMS (MiniMed, Slymar, CA) is approved for investigational use by FDA (Food and Drug Administration, U.S.A.), but is not designed to give real-time glucose information. It is designed to be worn subcutaneously for up to three days by the ambulant patient. The glucose readings collected by CGMS are meant to be downloaded onto a personal computer (PC). A daily retrospective analysis of glucose data is then performed by MiniMed's Solution Software V1.1A.
To use CGMS in real-time, the closed-loop system was designed to download BSL readings as collected by CGMS every five minutes. We used the inherent pre-programmed sensor calibration method described by MiniMed ® to estimate BSL. This calibration method (termed "Regression Calibration" 20 ) was applied in real-time, rather than as a once-off "post-processing" of data by MiniMed's Solution Software V1.1A.
The Controller
The controller was responsible for co-ordinating the download of BSL readings from the sensor, the calculation of insulin dose, the operation of the infusion pump, and the logging of all readings and associated events (e.g. alarms etc). The controller also prompted medical staff intervention when necessary. These controller functions were performed by in-house software running on a Intel ® Pentium III 800MHz PC with Windows ® 98 O/S. The investigators implemented the controller (which contains the algorithm) using software (rather than as firmware on an embedded microprocessor) because it gave them the flexibility to re-configure aspects of the controller when necessary during the conduct of clinical testing of the device.
The Infusion Pump
We used a pump which could be computer-controlled, namely the IMED Gemini ® PC-1 infusion pump (Alaris™ Medical Systems, San Diego CA). As the nursing staff in the ICU were already familiar with the IMED pump, any manual override of the computer's insulin prescription (due to over or under infusion) could be managed by the nursing staff. This obviated the need for additional staff training. Using the IMED Gemini ® PC-1 pump, the insulin infusion rate to the patient was adjusted automatically by the computer and delivered through an intravenous line attached to the patient as part of standard treatment.
The Algorithm
Clinical experience has shown that a sliding scale method of controlling high BSL is effective 21 . Our control algorithm was therefore based on the sliding scale approach. It was designed to be conservative in insulin infusion to avoid hypoglycaemia in the trial patients. The algorithm, and technical aspects of the closed-loop system are described elsewhere 22 .
Ethics Approval
The study was approved by the Ethics Committee of Sir Charles Gairdner Hospital, Perth, Western Australia and the Therapeutics Goods Administration (TGA), Canberra. Clinical testing was conducted in the Department of Intensive Care at Sir Charles Gairdner Hospital. The patient population from which trial patients were recruited consisted of adults over 18 years, but under 80 years, who had a BSL 10 mmol/l on admission to the Intensive Care Unit (ICU).
Written consent was obtained from patients, or their legal surrogates if they were unable. Each patient was entered only once into the trial, for a maximum of 24 hours.
Clinical Procedure
The glucose sensor was placed subcutaneously on the patient's anterior abdominal wall or on the outer aspect of the upper arm, as convenient. The monitor was connected to the sensor. The current measured by the sensor (viewed on the CGMS screen) was checked every five minutes for stability. Once the current fluctuated less than 10nA the sensor was initialized 20 . During initialization, CGMS attempts to stabilize the sensor, to prepare it for BSL measurement. Initialization normally takes one hour to complete.
Current practice in our ICU is to check BSL using blood drawn from an arterial line cannula as clinically indicated. The BSL readings are done using a MediSense ® 2 Blood Glucose Testing System (Abbott Laboratories, Bedford MA). This glucometer has an average coefficient of variation of 5%.
On completion of CGMS initialization, a glucometer reading was taken and entered into the CGMS within two minutes of measurement. This calibrated the CGMS in line with MiniMed's recommendation.
BSL was then measured by glucometer every two hours or as clinically indicated. As the glucometer reading was obtained, it was paired with the real-time CGMS BSL measurement as seen on the computer display and recorded. If the CGMS BSL deviated more than 3 mmol/l from the glucometer reading, then CGMS was re-calibrated (using the glucometer reading as the standard). This was done to ensure patient safety.
Pilot Study
In order to test the accuracy and the suitability of CGMS when used in real-time, a pilot study was designed. This correlated the real-time CGMS BSL readings and glucometer readings. It served as the basis for calibration of the closed-loop system. Three patients took part in the pilot study.
During the pilot study, patients continued to receive standard treatment. Insulin delivery rate was adjusted manually, according to a sliding scale currently used in the ICU. The subcutaneous glucose sensor was placed, but the closed-loop control system setup was used only to gather CGMS BSL readings and to verify the functionality of the system. 
Clinical Study
In the clinical study, the closed-loop system automatically downloaded BSL readings from CGMS and performed insulin rate adjustment using the built-in algorithm. During the clinical trial, the nursing staff also recorded their intended insulin dose (as if the closed-loop system were absent). This allowed the investigators to examine differences between the dose that would have been administered by the nursing staff and the dose actually delivered by the closed-loop system.
The performance of the system was investigated for the issues of interest listed in Table 1 . This report details the findings from the three pilot patients, and six patients who underwent clinical trials.
Statistical Analysis Analysis on Accuracy
To examine the accuracy of the sensor when used in real-time (in conjunction with the inherent preprogrammed calibration method), sensor BSL readings were compared with glucometer BSL's from after the initialization process to the end of the trial period (usually 24 hours). The trial period was divided into blocks of eight hours, and an average (and standard deviation) of the differences between the sensor BSL readings and the glucometer readings were taken for each block. This would allow us to examine the impact of using "regression calibration" in real-time BSL measurement.
The "Error Grid Analysis" as introduced by Clarke et al 23 was used to examine the clinical significance and safety of the BSL readings obtained. Error grid analysis (EGA) divides the grid (i.e. the plot of sensor BSL readings versus glucometer readings) into five zones of varying degrees of accuracy. Values lying in Zone A were deemed clinically accurate, in that they would lead to clinically acceptable treatment decisions. Upper and lower Zone B represent values that would lead to benign errors or no treatment. Zone C, D and E are potentially dangerous and may produce clinically significant errors. Two-way analysis of variance (ANOVA) was used to test for differences between the dose that would have been administered by the nursing staff and that actually delivered by the closed-loop system. The sources of variation in this hypothesis testing are the treatment methods (dose prescription in manual and closed-loop) and the patients (Patient J4, L0, H8, A0 and K4). The null hypothesis was that there is no difference between treatment methods, and no difference between patients.
Analysis on Efficiency
In order to investigate the effect of the closed-loop control system on the total time in which BSL stayed within a particular range, BSL was partitioned into four regions as shown in Table 2 .
An assessment was then made by examining the number of points (of BSL reading) in each region 24 hours before, during and 24 hours after the trial. Chisquare tests were performed to determine if closedloop control made a difference in the total time BSL stayed in Regions 1 and 2. The null hypothesis was that for each region there is no difference between closed-loop treatment and manual treatment.
Although CGMS gave continuous BSL readings, the "gold standard" was the glucometer reading for the purpose of this study. To reduce bias (where more points were taken when BSL was at a particular region), only BSL points that were more than one hour apart were used.
In assessing the performance of the closed-loop system against manual treatment, an average (and standard deviation) of arterial line BSL for 24 hours before, during and after the trial period were taken, and compared between patients and within patients.
Statistical analysis was done using Microsoft Excel ® 97, and R statistical computing and graphics package (R-Project Team, http://www.R-project.org). Figure 3 shows the plot of mean differences between sensor (CGMS) & glucometer BSL readings Total time BSL is between 6.1 mmol/l and 10 mmol/l 2
RESULTS
Pilot Study
The average value of BSL attained, and its variance The overall sensor-glucometer readings for these three patients (disregarding the time factor) was found to have a mean difference of -0.5±5.1 mmol/l (mean ± 1.96 xstandard deviation). Each of these three sensors performed differently in terms of their BSL deviation from the glucometer readings. Since we observed a decrease in deviation between sensor and glucometer readings with each successive patient, we decided to proceed with the larger clinical study. Figure 4 shows the blood glucose profile for the three patients in the pilot study.
Clinical Study
In the clinical study, once the initial insulin rate had been determined by clinical staff, the closed loop system was tested to see if it could maintain the patient's glycaemia approaching the target region of 6-10 mmol/l.
Out of six patients consented for closed-loop control, one was transported in and out of ICU for imaging procedures (CT scan and angiogram). Nursing staff inexperience with CGMS early in the trial resulted in the loss of real-time readings overnight for patient H2. The investigators therefore decided not to include the results for patient H2 in the statistical analysis. Figure 5 shows the mean sensor reading deviation from glucometer readings for five patients, plotted in blocks of eight hours.
The overall sensor reading deviation for Figure 5 has a mean difference of -0.1±5.5 mmol/l (mean± 1.96 xstandard deviation), while individual sensors performed differently over the clinical trial period. Figure 6 displays the closed-loop glucose control profile for the six closed-loop-controlled patients. To ensure patient safety, nursing staff were given instructions to adjust the insulin delivery rate manually if the closed loop system insulin dose was found to be inappropriate. Also, when a large variation between sensor reading and glucometer reading was observed, a calibration was done (to bring the sensor reading closer to the glucometer reading). This is shown in Figure 6 by a diamond dot with a straight line adjoining two sensor readings, (depicting an increase or decrease in sensor reading).
To reduce the risk of hypoglycaemia in patients, it was deemed more acceptable for the sensor BSL reading to read lower than the glucometer reading, instead of higher (resulting in higher delivered doses of insulin). At sensor reading points which were 2 mmol/l lower than glucometer BSL points, no calibration was done, although this was left to clinical discretion.
Where the sensor reading was high while the glucometer read low, manual correction of insulin represents the glucometer BSL entered into CGMS as calibration points, represents CGMS BSL readings in mmol/l, and ∆ are the glucometer readings taken every 2 hours for comparison (also called Meter BSL) in mmol/l. Two sensors were inserted for patient A0 due to an unexpected fluctuation in the BSL readings of the first sensor.
Comparison of sensor to glucometer BSL (Table 3 ) showed that 64.6% of the BSL readings were clinically acceptable (Zone A), while 30.9% would lead to no treatment (Zone B). The remaining 4.4% of the readings which lay in Zone D & E were obtained from one sensor. Figure 7 presents a graphical representation of the accuracy of the readings.
Two-way ANOVA analysis ( Table 4 ), showed that "between patients" variation was statistically significant (P<0.05). There appeared to be no difference in the dose as prescribed by the closed-loop system, and that predicted by the nursing staff (P value= 0.178).
Chi-square tests results suggested no apparent difference between the manual treatment methods before and after the trial for Regions 1 or 2 (P value of 0.950 and 0.909). Yates' continuity correction was added to compensate for the small sample size 24 . This was expected since both methods are essentially the same (i.e. both are manual control).
There was also no significant difference between closed-loop and manual control in terms of BSL staying in Region 1 (average P values ²0.5) and Region 2 (average P values ²0.2). Table 5 shows the averaged BSL and standard deviation attained 24 hours before, during and 24 hours after the trial. FIGURE 6a-f continued 6d 6f 6e Figure 9 shows an average of the sensor BSL readings from eight patients, plotted against time. The averaged BSL readings, together with standard error of the mean (SEM) gives an indication as to the "tightness" of closed-loop BSL control (i.e. less variation of BSL for all eight patients after 10 hours of trial).
DISCUSSION
The results above illustrate the performance of a closed-loop system for control of BSL in critically ill patients. The closed-loop system maintained a BSL close to the target range, with less variation in BSL, compared to BSL maintained manually. The results also showed that the closed-loop system was able to maintain BSL within the range 10 to 15 mmol/l, albeit not within the 6 to 10 mmol/l range. The maintenance of BSL in the higher BSL range is partly due to our algorithm being programmed to be conservative in insulin delivery to avoid hypoglycaemia. Results from the Chi-square test and ANOVA analysis suggested that the closed-loop system and manual control method are equally effective in BSL control in this group of patients.
Most patients admitted to the ICU had a degree of peripheral oedema. Glucose monitoring based on subcutaneous interstitial fluid may be affected by this. In one case (Patient A0), glucose values obtained from the sensor placed in subcutaneous tissue in the abdomen, fluctuated greatly, and the sensor had to be re-sited in the upper arm to reduce this. After this incident, the sensor was preferentially inserted in the upper arm of Patient K4. Good tracking was obtained, despite an initial surge in the readings for the first few hours. Although sensor BSL deviated from the glucometer BSL in Patient K4, no re-calibration was done.
There was one incident where sensor readings appeared to deviate greatly from the glucometer reading throughout the trial period (Patient J4). A retrospective analysis showed that the sensor reading was delayed by about one hour with respect to the glucometer reading. Whether this delay was due to the internal signal processing of CGMS, or the time lag between interstitial fluid glucose levels and plasma glucose levels (which was reported to be up to 45 minutes 25 ), or even both, is unclear. The authors found that during an in vitro test of the sensors used on Patient J4, the signal processing of CGMS stretched the response time from 20 minutes up to 33 minutes for a step increase (of 5 mmol/l) of glucose concentration.
During the closed-loop clinical study, five manual interventions were required because of a more than 20% deviation in sensor BSL from glucometer BSL. Two manual interventions (on Patient H8 and Patient K4) were to prevent a possible hypoglycaemic episode by acting prior to the activation of the automatic protection scheme. This is only activated when BSL fell below 7 mmol/l. The remaining manual adjustments by nursing staff were also precautionary (Patient A0).
Results from Patient A0 revealed details of the localization of BSL within a particular region by the algorithm. Patient K4 showed that the algorithm may be further improved by raising the threshold BSL required for immediately reducing the insulin infusion on detection of a rapid drop in BSL. The sensor accuracy of 64.6% was obtained only with frequent recalibration of the sensor (on detection of greater than 3 mmol/l deviation). However CGMS has the potential to be used with just one initial calibration. This is evident from Patient L0, where with a deviation of only 1 mmol/l, the sensor closely tracked the patient's glycemia. The closedloop system was able to maintain the BSL without any manual intervention. With sensor accuracy of within 1 mmol/l, a less conservative insulin delivery scheme could be implemented to further lower BSL to within 6 to 10 mmol/l. The authors concluded that if sensor BSL deviation can be kept to within 20% of glucometer BSL, either by an improvement in the sensor construct or by a better calibration technique, then the closed-loop system has the potential to be used without manual intervention. It is acknowledged that the sensor was used in this study in a manner (real-time) for which it is not designed. Also, the patient population (with subcutaneous oedema a common finding) is probably not ideal for use of this device. Nevertheless it was reasonable to use the sensor in these patients due to the high level of vigilance. 
P values P values for Pearson's Chi-Square Test (with Yates' continuity correction) for 5 clinical trial patients
The sensor reading may be influenced by factors such as the state of patient's skin perfusion, other chemical compounds (e.g. medication) within the subcutaneous space that can be oxidized apart from glucose, sensor insertion site and signal processing of CGMS.
The present method of using "regression calibration" for real-time subcutaneous glucose measurement has considered all the calibration points entered since the beginning of the clinical study. This method will require refinement, especially if the interval of sensor use spans more than 24 hours, because the sensitivity of the glucose sensor may change with time 20 . One example of refinement would be to disregard the calibration points which were 24 hours old, and only use the recently entered calibration points instead.
Experience with use of the CGMS Out of 14 sensors used, we managed to obtain only nine satisfactory results. In five of the accidentally removed sensors, one was dislodged during patient handling, one had its connection short-circuited due to blood being drawn up the sensor strip via capillary action, one was removed due to inexperience in using the sensor, and two had unsatisfactory readings due to possible improper site selection. We occasionally found mismatch in BSL readings time stamp where two subsequent downloaded files (five minutes apart) showed a difference in their time stamp of up to one hour. These experiences will be used subsequently to improve the clinical trial handling.
CONCLUSION
We have described the development of a closed loop system to control BSL in critically ill patients. The main drawback of the system is the inaccuracy of the subcutaneous sensor, requiring frequent recalibration when used in the real-time setting. Despite this, closed loop control provided acceptable glycaemic control, comparable to manual BSL control. Further development of the system is required before it is suitable for routine clinical use. The encouraging results to date, the ongoing progress in sensor development and the strong clinical imperative for good glycaemic control 26 encourage the authors to continue development of this system.
